FDA's plan to boost cheaper copycat drugs could stall at patent office
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the opposite direction.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief